Interim Reports
Latest Reports
Interim Report 3 2024/25
Sales grew significantly for both Q3 and YTD, outperforming the FY results of the previous year. Gross margin continues to be strong, even slightly above planned levels (+4pp). Overall costs remain stable and as per plan, with higher administrative costs due to the capital raise offset by lower R&D expenses. The absolute key to transforming the Company, both short-term and long-term, is a significant increase in sales, which is expected due to a strong pipeline and company potential.
Learn more …
Interim Report 2 2024/25
Sales grew significantly in Q2 vs. the same period last year, but only moderately YTD vs. the same period last year. Discounting on demo kits for our new distributors reduced the gross margin. Overall costs remain stable. The absolute key to transforming the company, both short-term and long-term, is a significant increase in sales, which the agreement with Altium promises to deliver.
Learn more …
Interim Report 1 2024/25
The first quarter of 2024 has so far been a period of steady course and strategic positioning for Phase Holographic Imaging. Most notably, PHI has been very active around the globe in forming important academic and sales partnerships during this summer and preparing for future growth.
Learn more …
Interim Report 4 2023/24
This spring has been a dynamic and productive period for PHI, as our team and partners have made significant efforts on multiple fronts. Externally, our collaboration with Altium has focused on expanding our sales processes and networks and enhancing our market presence. Internally, our dedicated team has been advancing our ongoing regenerative medicine projects and refining our HoloMonitor technology.
Learn more …
Interim Report 3 2023/24
This quarter set new records for PHI, achieving our highest-ever sales and advancing our strategic initiatives significantly. The strengthening of our partnership with Altium and the expanding reach of QPI technology highlights our leading position in the field. This quarter truly shows our continuous progress toward our core mission: making cell-based therapies accessible, affordable, and safe for all.
Learn more …
Interim Report 2 2023/24
The autumn quarter marked a strategic shift in our sales organization, representing a significant move for PHI but affecting our Q2 sales. It allows us to sharpen our focus on what we do best: innovation and product development, particularly toward regenerative medicine applications.
Learn more …
Interim Report 1 2023/24
During this past summer quarter, we made it our most prosperous Q1 quarter to date, characterized by sustained growth.
Learn more …
Interim Report 4 2022/23
Sales continue to grow, and the year ended up with the highest turnover for a year in PHI, so far.
Learn more …
Interim Report 3 2022/23
Sales have continued to grow, with significantly higher cost efficiency. As a result, rolling 12-month sales gained to its highest level ever.
Learn more …
Interim Report 2 2022/23
The online sales and lead generation strategy continues to deliver. As a result, sales from August to October this year reached 2.7 KSEK — an increase of 50 % compared to any previous corresponding period.
Learn more …
Interim Report 1 2022/23
Despite a summer-sluggish period ending in July, sales were just one unit away from surpassing our best quarter ever; the same period last year.
Learn more …
Year-end Report 2021/22
Sales more than doubled in 2021/22, compared to previous financial year.
Learn more …
Interim Report 2 2021/22
Strong sales growth for the 3rd consecutive quarter. Recent advancements in regenerative medicine create additional growth potential in clinical applications for the company.
Learn more …